Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share ...

Moderna (MRNA) has clearly outperformed after announcing an Oct. 24 presentation that will include additional late-stage trial data for its cancer shot developed with Merck (MRK), even as analysts ...

Moderna stock is a "Hold" due to persistent unprofitability, negative free cash flow, and a valuation highly dependent on ...

Shares of Nike Inc. NKE, Moderna Inc. MRNA and Walmart Inc. WMT climbed Thursday as money flowed out of tech and AI stocks ...

Moderna stock gains on reports of an initiative to accelerate cancer vaccine development. Here’s why caution is warranted in ...

Moderna stock rallied by triple digits when positive news rolled in for its cancer vaccine. But is mRNA ready to return to the limelight?

Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine ...

CAMBRIDGE, MA / ACCESS Newswire / October 13, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a ...

Healthcare is drawing fresh buying as money moves away from the market’s popular technology trade, and one messenger RNA ...

Following last month's super rally, a growing number of analysts are now calling for caution.

Billionaire biotech mogul Noubar Afeyan has called for urgent regulation of artificial intelligence agents that tech firms ...

Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds ...